221 related articles for article (PubMed ID: 32862515)
21. Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection.
Sugawara T; Ban D; Nishino J; Watanabe S; Maekawa A; Ishikawa Y; Akahoshi K; Ogawa K; Ono H; Kudo A; Tanaka S; Tanabe M
PLoS One; 2021; 16(4):e0249885. PubMed ID: 33844700
[TBL] [Abstract][Full Text] [Related]
22. CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery.
Hsu CP; Lee LY; Hsu JT; Hsu YP; Wu YT; Wang SY; Yeh CN; Chen TC; Hwang TL
In Vivo; 2018; 32(6):1533-1540. PubMed ID: 30348713
[TBL] [Abstract][Full Text] [Related]
23. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
24. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
25. Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma.
Rittmann MC; Hussung S; Braun LM; Klar RFU; Biesel EA; Fichtner-Feigl S; Fritsch R; Wittel UA; Ruess DA
Sci Rep; 2021 Apr; 11(1):7499. PubMed ID: 33820913
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ductal adenocarcinoma.
Liang Y; Sheng G; Guo Y; Zou Y; Guo H; Li Z; Chang S; Man Q; Gao S; Hao J
Cancer Biol Med; 2024 Jan; 21(5):. PubMed ID: 38172499
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of exosome-encapsulated microRNA-451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcinoma.
Takahasi K; Iinuma H; Wada K; Minezaki S; Kawamura S; Kainuma M; Ikeda Y; Shibuya M; Miura F; Sano K
J Hepatobiliary Pancreat Sci; 2018 Feb; 25(2):155-161. PubMed ID: 29130611
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery.
Li S; Xu H; Wu C; Wang W; Jin W; Gao H; Li H; Zhang S; Xu J; Zhang W; Xu S; Li T; Ni Q; Yu X; Liu L
Cancer Med; 2019 Feb; 8(2):572-584. PubMed ID: 30632317
[TBL] [Abstract][Full Text] [Related]
29. Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma.
Yang Z; Senninger N; Flammang I; Ye Q; Dhayat SA
J Cancer Res Clin Oncol; 2019 May; 145(5):1165-1178. PubMed ID: 30778748
[TBL] [Abstract][Full Text] [Related]
30. Does Size Matter in Pancreatic Cancer?: Reappraisal of Tumour Dimension as a Predictor of Outcome Beyond the TNM.
Marchegiani G; Andrianello S; Malleo G; De Gregorio L; Scarpa A; Mino-Kenudson M; Maggino L; Ferrone CR; Lillemoe KD; Bassi C; Castillo CF; Salvia R
Ann Surg; 2017 Jul; 266(1):142-148. PubMed ID: 27322188
[TBL] [Abstract][Full Text] [Related]
31. Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future.
Barhli A; Cros J; Bartholin L; Neuzillet C
Dig Liver Dis; 2018 Oct; 50(10):979-990. PubMed ID: 30205952
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of intraoperative peritoneal washing cytology for patients with potentially resectable pancreatic ductal adenocarcinoma.
Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Hoshi N; Hoshi S; Hirabayashi K; Ogata Y
Pancreatology; 2017; 17(1):109-114. PubMed ID: 27840175
[TBL] [Abstract][Full Text] [Related]
33. High overall copy number variation burden by genome-wide methylation profiling holds negative prognostic value in surgically treated pancreatic ductal adenocarcinoma.
Detlefsen S; Boldt HB; Burton M; Thomsen MM; Rasmussen LG; Ørbeck SV; Pfeiffer P; Mortensen MB; de Stricker K
Hum Pathol; 2023 Dec; 142():68-80. PubMed ID: 37977512
[TBL] [Abstract][Full Text] [Related]
34. Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study.
Zou S; Wang X; Chen H; Lin J; Wen C; Zhan Q; Chen H; Lu X; Deng X; Shen B
BMC Cancer; 2022 Jun; 22(1):649. PubMed ID: 35698045
[TBL] [Abstract][Full Text] [Related]
35. Reappraisal of nodal staging and study of lymph node station involvement in distal pancreatectomy for body-tail pancreatic ductal adenocarcinoma.
Malleo G; Maggino L; Nobile S; Casciani F; Cacciatori N; Paiella S; Luchini C; Rusev B; Capelli P; Marchegiani G; Bassi C; Salvia R
Eur J Surg Oncol; 2020 Sep; 46(9):1734-1741. PubMed ID: 32327367
[TBL] [Abstract][Full Text] [Related]
36. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
Sun B; Liu X; Gao Y; Li L; Dong Z
Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
39. Reappraising the Concept of Conditional Survival After Pancreatectomy for Ductal Adenocarcinoma: A Bi-institutional Analysis.
Malleo G; Maggino L; Ferrone CR; Marchegiani G; Warshaw AL; Lillemoe KD; Bassi C; Castillo CF; Salvia R
Ann Surg; 2020 Jun; 271(6):1148-1155. PubMed ID: 30339622
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of Ki-67 proliferative index in resectable pancreatic ductal adenocarcinoma.
Pergolini I; Crippa S; Pagnanelli M; Belfiori G; Pucci A; Partelli S; Rubini C; Castelli P; Zamboni G; Falconi M
BJS Open; 2019 Oct; 3(5):646-655. PubMed ID: 31592095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
